Amplify Alternative Harvest ETF (NYSEARCA:MJ) Shares Up 1.3% – Still a Buy?

Amplify Alternative Harvest ETF (NYSEARCA:MJ) shares traded up 1.3% during trading on Monday . The stock traded as high as $20.82 and last traded at $20.56. 52,145 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 76,402 shares. The stock had previously closed at $20.30.

Amplify Alternative Harvest ETF Stock Performance

The firm has a 50 day simple moving average of $24.39 and a two-hundred day simple moving average of $30.96. The stock has a market cap of $118.63 million, a P/E ratio of 16.72 and a beta of 1.25.

Hedge Funds Weigh In On Amplify Alternative Harvest ETF

Several large investors have recently bought and sold shares of MJ. Raffles Associates LP acquired a new position in shares of Amplify Alternative Harvest ETF during the 4th quarter valued at $1,176,000. Jaffetilchin Investment Partners LLC boosted its stake in Amplify Alternative Harvest ETF by 26,197.0% during the fourth quarter. Jaffetilchin Investment Partners LLC now owns 473,083 shares of the company’s stock valued at $1,060,000 after buying an additional 471,284 shares in the last quarter. Quinn Opportunity Partners LLC grew its holdings in Amplify Alternative Harvest ETF by 26.5% during the fourth quarter. Quinn Opportunity Partners LLC now owns 1,308,825 shares of the company’s stock worth $2,932,000 after acquiring an additional 274,441 shares during the period. Millennium Management LLC bought a new stake in Amplify Alternative Harvest ETF in the fourth quarter worth about $494,000. Finally, Raymond James Financial Inc. acquired a new stake in Amplify Alternative Harvest ETF in the 4th quarter valued at about $223,000.

Amplify Alternative Harvest ETF Company Profile

The ETFMG Alternative Harvest ETF (MJ) is an exchange-traded fund that is based on the Prime Alternative Harvest index. The fund tracks an index of global firms engaged in the legal cultivation, production, marketing or distribution of cannabis, cannabinoids or tobacco products. The portfolio is weighted by market cap or equally based on a proprietary system.